Physician profile
Douglas Tyler
NPI 1447357249
$5,738.31
in general payments reported to CMS, 2019-2025
33 companies · $942 in 2025
The $942 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $904 · 2020: $230 · 2021: $1,106 · 2022: $861 · 2023: $895 · 2024: $801 · 2025: $942.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,638.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,637.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,071.09 | 2019-2025 | Repatha, Otezla, Repatha |
| Abbvie INC. | $875.16 | 2019-2024 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $485.71 | 2019-2025 | |
| Lilly USA, LLC | $234.11 | 2020-2025 | Zepbound, Mounjaro, Kisunla |
| Novo Nordisk INC | $121.77 | 2023 | Wegovy |
| Allergan, INC. | $112.15 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $74.76 | 2021-2025 | Breztri |
| Csl Behring | $72.65 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $66.65 | 2019-2022 | |
| Curonix LLC | $50.38 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Merck Sharp & Dohme LLC | $47.32 | 2023 | Dificid |
| Merz Pharmaceuticals, LLC | $44.37 | 2023-2024 | Xeomin |
| Pfizer INC. | $43.89 | 2021 | |
| Akcea Therapeutics, INC. | $32.89 | 2019 | |
| Neurocrine Biosciences, INC. | $30.70 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $30.21 | 2019 | |
| Supernus Pharmaceuticals, INC. | $29.53 | 2021 | |
| Almatica Pharma LLC | $28.40 | 2021 | |
| Edwards Lifesciences Corporation | $25.53 | 2021 | |
| Mallinckrodt Hospital Products INC. | $24.65 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $23.07 | 2021 | |
| Impel Pharmaceuticals INC. | $23.06 | 2022 | |
| Eisai INC. | $22.79 | 2021 | |
| Alexion Pharmaceuticals, INC. | $21.82 | 2021 | |
| Tanabe Pharma America, INC. | $19.61 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.57 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.24 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.80 | 2019 | |
| Genentech USA, INC. | $15.05 | 2021 | |
| Glaxosmithkline, LLC. | $13.73 | 2023 | Arexvy, Shingrix |
| Exact Sciences Corporation | $13.66 | 2023 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.63 | 2024 | Xifaxan |
| Ibsa Pharma INC. | $13.36 | 2024 | Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Tyler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.